Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Adenosine Phosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 known ✓ | P47900 | 9/20 | 0.83 |
| ▸ | P2RY2 known ✓ | P41231 | 3/20 | 0.83 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.83 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.83 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.83 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.83 |
| ▸ | SRC | P12931 | 2/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.83 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.83 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.83 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.83 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.83 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.83 |
| ▸ | LDHA | P00338 | 1/20 | 0.83 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.83 |
| ▸ | FBP1 | P09467 | 1/20 | 0.83 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.83 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.83 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine Phosphate SCHEMBL29574456 | 1.00 | P2RY1 (0.83) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL29558795 | 0.98 | P2RY1 (0.83) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL8425208 | 0.97 | P2RY1 (0.89) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL28252058 | 0.97 | P2RY1 (0.81) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL29364783 | 0.94 | P2RY1 (0.83) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL353218 | 0.94 | P2RY1 (0.83) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL1356934 | 0.94 | P2RY1 (0.83) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL145417 | 0.94 | P2RY1 (0.83) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL23093554 | 0.93 | P2RY1 (0.81) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL9068130 | 0.93 | P2RY1 (0.81) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117467715-A | Process for simultaneously preparing D-glutamic acid and L-glutathione by multi-step enzyme method | 珠海瑞德林生物有限公司 | 2024-01-30 | — | — | CN | claimed |
| CN-112707966-A | Protein and hierarchical pore metal-organic framework compound and preparation method and application thereof | 华南理工大学 | 2021-04-27 | — | — | CN | claimed |
| US-12533371-B2 | Multilayer pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and b vitamins, preparation and uses thereof | FERRER INTERNACIONAL, S.A. (ES) | 2026-01-27 | — | — | US | disclosed |
| CN-116410938-B | Beta-alanine ligase mutant and application thereof | 深圳瑞德林生物技术有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117467715-A | Process for simultaneously preparing D-glutamic acid and L-glutathione by multi-step enzyme method | 珠海瑞德林生物有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-113784706-B | Multi-layered pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and B vitamins, their preparation and use | 菲尔若国际公司 | 2024-01-05 | — | — | CN | disclosed |
| EP-3335693-B1 | COMPOSITION FOR EXTERNAL USE | OTSUKA PHARMA CO LTD (JP) | 2023-09-13 | — | — | EP | disclosed |
| CN-116410938-A | Beta-alanine ligase mutant and application thereof | 深圳瑞德林生物技术有限公司 | 2023-07-11 | — | — | CN | disclosed |
| CN-116376853-A | Beta-alanine ligase mutant and application thereof | 深圳瑞德林生物技术有限公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-115820578-A | Mutant composition, fusion enzyme and preparation method of collagen tripeptide | 深圳瑞德林生物技术有限公司 | 2023-03-21 | — | — | CN | disclosed |
| US-20220160744-A1 | MULTILAYER PHARMACEUTICAL OR NUTRACEUTICAL SOLID DOSAGE FORMS COMPRISING PYRIMIDINE AND/OR PURINE DERIVATIVES AND B VITAMINS, PREPARATION AND USES THEREOF | FERRER INTERNACIONAL, S.A. (ES) | 2022-05-26 | — | — | US | disclosed |
| US-20050220827-A1 | Chloasma amelioration composition and dullness amelioration composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
| US-20050222076-A1 | Composition for cell proliferation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
| US-6946436-B2 | O/W emulsion composition and method of preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-09-20 | — | — | US | disclosed |
| EP-1512405-A1 | CHLOASMA AMELIORATION COMPOSITION AND DULLNESS AMELIORATION COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1498101-A1 | COMPOSITION FOR CELL PROLIFERATION | Otsuka Pharmaceutical Company, Limited (JP) | 2005-01-19 | — | — | EP | disclosed |
| US-20040116373-A1 | Sugar intake promoters | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| US-20040029761-A1 | O/W emulsion composition and method of preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-12 | — | — | US | disclosed |
| EP-1378224-A1 | SUGAR INTAKE PROMOTERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-07 | — | — | EP | disclosed |
| EP-1342462-A1 | O/W EMULSION COMPOSITION AND METHOD OF PREPARING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533371-B2 | Multilayer pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and b vitamins, preparation and uses thereof | P2RY10, TYMP, P2RY12 | P2RY1 14/4885P2RY2 42/4885ADORA1 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.